SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kobo Biotech Ltd (531541)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531541 NSE: Pharmaceuticals & Drugs | Small Cap | Kobo Biotech Share Price

₹8.75 0.17 (1.98%)

As on 08-Jul'26 16:59

Kobo Biotech Ltd (531541)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531541 NSE: Pharmaceuticals & Drugs | Small Cap | Kobo Biotech Share Price

₹8.75 0.17 (1.98%)

As on 08-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹21 Cr.
Current Price
₹8.8
52-Week Low / High
₹2 / 9
TTM EPS
₹-2.2
TTM Sales
₹0 Cr.
Book Value per Share
₹-58
P/E Ratio
0.00
Industry PE
49.2
Price to Book (P/B)
-0.15
Lower than its 5-year historical median
Price to Sales (P/S)
0.00
EV/EBITDA
-134.84
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Underperforms industry median
Return on Capital Employed (ROCE)
-125.54%
Underperforms industry median
Return on Assets (ROA)
-7.32%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
44.95%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-162 Cr.
Equity
₹23.8 Cr.
Face Value
₹10
All Time Low / High
₹1.19 / 82.55

Kobo Biotech stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Kobo Biotech Ltd a good quality company?
Kobo Biotech Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Kobo Biotech Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Kobo Biotech Ltd vs industry peers?
Kobo Biotech Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 6.81%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Kobo Biotech Ltd?
Promoters hold 44.95% of the Kobo Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Kobo Biotech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -10.3% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kobo Biotech Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -1.3%-2.8%-5.1%-5.7%-3.9%-5.3%-17.6%-36.8%-52.9%-125.5%-
Value Creation
Index
-1.1NANANANANANANANANA-

Growth Parameters

Sales 32.50000000000
Sales YoY Gr.--100%NANANANANANANANA-
Adj EPS -7.2-8-10.1-10-9.4-7.9-0.2-2.2-2.1-2.1-2.2
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 0.2-7.8-17.8-28.1-36.9-45-51.4-53.7-55.8-58-58
Adj Net
Profit
-17.1-19.2-24-23.8-22.4-18.8-0.4-5.2-4.9-5.1-5
Cash Flow from Ops. 5.632.331.52114.52.593.80.92.64.2-
Debt/CF from Ops. 27.26.47.111.317.3103.81.5159.954.633.5-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -100%NANANA
Adj EPS NANANANA
BVPS-291.2%NANANA
Share Price -0.3% 8.1% 57.5% 231.4%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-170.2315.378.543.528.919.30.44.13.83.83.8
Op. Profit
Mgn %
11.9000000000NAN
Net Profit
Mgn %
-52.6000000000-INF
Debt to
Equity
384.1-11.2-5.2-3.5-2.9-2.4-1.2-1.1-1.1-1-
Working Cap
Days
1,6750000000000
Cash Conv.
Cycle
7110000000000

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales32.54000000000
Operating Expenses + 28.664.043.082.992.612.79143.871.500.871.23
Manufacturing Costs3.410.340.240.310.420.280.100.120.140.06
Material Costs19.50000000000
Employee Cost 4.273.112.422.081.801.390.720.230.250.19
Other Costs 1.490.590.420.600.391.11143.051.150.480.99
Operating Profit 3.88-4.04-3.08-2.99-2.61-2.79-143.87-1.50-0.87-1.23
Operating Profit Margin (%) 11.9%---------
Other Income + 1.3560.101.311.950.04133.380.020.020.08
Exceptional Items 000-2.18000000
Interest 14.3714.4114.5014.4414.4710.840.13000
Depreciation 7.316.786.446.155.885.644.614.074.074.07
Profit Before Tax -16.46-19.24-23.92-24.46-21.01-19.23-15.23-5.55-4.93-5.23
Tax 0000000000
Profit After Tax -16.46-19.24-23.92-24.46-21.01-19.23-15.23-5.55-4.93-5.23
PAT Margin (%) -50.6%---------
Adjusted EPS (₹)-6.9-8.1-10.0-10.3-8.8-8.1-6.4-2.3-2.1-2.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Kobo Biotech - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 0.40-18.58-42.51-66.96-87.97-107.20-122.43-127.98-132.91-138.14
Share Capital 23.7323.8323.8323.8323.8323.8323.8323.8323.8323.83
Reserves -23.33-42.41-66.33-90.79-111.80-131.03-146.25-151.81-156.74-161.97
Debt +134.91179.17176.56184.46198.86208.2693.2992.4291.4791.47
Long Term Debt39.2858.4141.4334.9334.9333.5333.5332.6631.7131.71
Short Term Debt95.63120.76135.13149.53163.93174.7359.7659.7659.7659.76
Minority Interest0000000000
Trade Payables58.3450.1051.5154.4657.0860.4552.1754.7455.7856.90
Others Liabilities 66.8241.5360.3867.4968.3669.0856.1556.1657.0561.35
Total Liabilities 260.47252.22245.94239.45236.33230.5979.1975.3371.3971.59

Fixed Assets

Net Fixed Assets +87.7981.0174.5668.4262.5456.9141.6637.5933.5229.44
Gross Block192.41192.41192.41192.42192.42192.42103.68103.68103.68103.68
Accumulated Depreciation104.62111.41117.85124129.88135.5162.0266.0970.1674.23
CWIP 2.252.252.252.252.252.250000
Investments 12.1912.1912.1912.1912.1912.190000
Inventories55.4655.4655.4653.2853.2853.2818.0418.0418.0418.04
Trade Receivables89.7388.7488.8390.6193.2992.4711.8011.9511.9712.01
Cash Equivalents 0.590.130.130.130.131.560.130.130.184.36
Others Assets 12.4512.4412.5112.5712.6511.937.567.627.697.73
Total Assets 260.47252.22245.94239.45236.33230.5979.1975.3371.3971.59

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 5.6232.3031.4720.9514.482.5193.760.872.564.18
PBT -16.46-19.24-23.92-24.46-21.01-19.23-15.23-5.55-4.93-5.23
Adjustment 21.6921.1920.9420.5920.3516.484.744.074.074.07
Changes in Working Capital 0.3930.3534.4524.8215.135.26104.242.363.425.33
Tax Paid 0000000000
Cash Flow From Investing Activity + 000-0-0025.0904.070
Capex 000-0-0012.8904.070
Net Investments 00000012.19000
Others 0000000.01000
Cash Flow From Financing Activity + -5.27-32.76-31.47-20.95-14.47-1.08-120.28-0.87-1.020
Net Proceeds from Shares 3.190.2600000000
Net Proceeds from Borrowing -0.11-12.59-16.97-6.500-1.400-0.87-1.820
Interest Paid -14.37-14.41-14.50-14.44-14.47-10.84-0.13000
Dividend Paid 0000000000
Others 6.03-6.0300011.16-120.1500.800
Net Cash Flow 0.35-0.460-0-01.43-1.4305.614.18

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-233.98N/AN/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)-1.32N/AN/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0.13000000000
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days815.20000000000
Inventory Days700.90000000000
Payable Days1,028000000000

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kobo Biotech Ltd FAQs

The current trading price of Kobo Biotech on 08-Jul-2026 16:59 is ₹8.75.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 07-Jul-2026 the market cap of Kobo Biotech stood at ₹20.85 Cr

The latest P/E ratio of Kobo Biotech as of 07-Jul-2026 is 0.00.

The latest P/B ratio of Kobo Biotech as of 07-Jul-2026 is -0.15.

The 52-week high of Kobo Biotech is ₹8.75 and the 52-week low is ₹1.99.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kobo Biotech is ₹0.00 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kobo Biotech Ltd is a average quality company.

The key valuation ratios of Kobo Biotech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kobo Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Kobo Biotech Ltd

AVON Organics Limited (AOL) was started by P R Agarwal, Rajesh Agarwal along with late G S Sidhu .It is located at Madhupala Towers Greenlands, Hyderabad 500 016, India. The company's transition from a machinery manufacturer to a full-fledged chemical manufacturer saw the company foraying into the highly technology-intensive area of Diketene and its derivatives.

In the year 1996 the company established and successfully commissioned its first grass root Diketene plant .It has doubled its production capacity by commissioning an additional 1000 TPA unit as part of its second phase in 1998.  It is an ISO 9000 certification by the Lloyds Register Quality Assurance (LRQA).

Business profile:

A keen insight and a well-planned development process saw AOL discover the opportunity in the production of Diketene - the basic unit for hundreds of derivatives in pesticides, chemicals, pharmaceuticals and dyestuffs. A highly classified technology, it has been sourced from Shanghai Peng Pu Chemical Works, China, and Xytel Technology Partnership, USA, and now rests in the hands of a few chosen manufacturers across the globe.

The company, with its immense infrastructure framework has introduced modifications to the Chinese technology and has a current production of 3000 tonnes per annum against an installed capacity of 2000 tonnes per annum. A sprawling facility of 21 acres, the plant is situated 60 kilometers from Hyderabad. The locale is ideal due to its easy connectivity made possible by the well-traversed National Highway # 9 that links Hyderabad with Mumbai.

Products :

  • Diketene:
  • Pharmaceutical intermediates
  • Agrochemical intermediates
  • Pigment intermediates 

Pharmaceutical (Including Ephedrines) :

  • Active Pharmaceutical ingredients
  • Pharma intermediates
  • Formulation intermediates 
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: